New blank-check company Deep Medicine Acquisition registered with the SEC to offer 10 million units at $10 each. A unit consists of one share and one right. Each right entitles the holder to receive one-tenth of a share upon completion of a business combination.
Deep Medicine seeks a target in the healthcare industry with an equity value of approximately $300 million to $1 billion.
The special purpose acquisition company is led by CEO and Chairman Humphrey P. Polanen, who is CEO and managing member of NeoVista Ventures, a private equity fund.
The SPAC intends to apply for a Nasdaq listing under DMAQU. Read more.